IP Library › Granted Patent US 12,319,722
Granted Patent B2
US 12,319,722 · App. 17/254,004 · Granted Jun 3, 2025

Interleukin-15 (IL-15) fusion proteins and uses thereof

Inventors: Yue-Sheng Li (Thousand Oaks, CA); Lingyun Rui (Weston, MA); Jing Xu (Waltham, MA)
Assignee: Cugene Inc
C07K14/5443A61P35/00C07K14/7155A61K38/00C07K1/14C07K2319/30C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,319,722
App. No.
17/254,004
Granted
Jun 3, 2025
Kind
B2
Abstract

The present disclosure provides novel and improved IL-15 fusion proteins for use in the treatment of cancer and other disorders. In various embodiments, the fusion proteins of the invention have two functional domains: an IL-15/IL-15RαSushi domain (also referred to herein as an “IL-15/IL-15RαSushi complex”) and an Fc domain, each of which can take different forms, and configured such that the IL-15 is fused to the C-terminal of the Fc domain and co-expressed and non-covalently complexed with IL-15RαSushi. Importantly, the fusions proteins of the present invention address several of the limitations observed with the IL-15 therapeutics evaluated to date; specifically, the fusion proteins demonstrate extended the half-life of IL-15 in vivo, and demonstrate superior preclinical activity compared to rIL-15 or related cytokine therapeutics.

Claims (12)

1. An isolated Interleukin-15 (IL-15) fusion protein complex comprising: (1) an IL-15 polypeptide (or variant thereof) linked to an Fc domain; and (2) an IL-15 Receptor alpha (“IL-15Rα”) domain noncovalently linked to the IL-15 polypeptide to form an IL-15/IL-15Rα-Fc fusion protein complex; wherein the IL-15 polypeptide is an IL-15 variant polypeptide comprising a substitution of S to D at position 58 of SEQ ID NO: 2; wherein the fusion protein complex is selected from the group consisting of a fusion protein complex wherein the IL-15 polypeptide is linked to the C-terminus of the Fc domain and a fusion protein complex wherein the IL-15 polypeptide is linked to the N-terminus of the Fc domain.

2. The IL-15/IL-15Rα-Fc fusion protein complex according to claim 1 , wherein the IL-15Rα domain is an IL-15 Receptor alpha Sushi (“IL-15RαSushi”) domain and comprises an amino acid sequence that is at least 90% homologous to the sequence set forth in SEQ ID NO: 5.

3. The IL-15/IL-15Rα-Fc fusion protein complex according to claim 1 , wherein the Fc domain is an Fc domain having an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8; and wherein the IL-15 polypeptide is covalently attached to an Fc domain by a peptide linker.

4. A pharmaceutical composition comprising an IL-15/IL-15Rα-Fc fusion protein according to claim 1 in admixture with a pharmaceutically acceptable carrier.

5. An isolated IL-15 fusion protein complex comprising: (1) an IL-15Rα domain linked to an Fc domain; and (2) an IL-15 polypeptide (or variant thereof) noncovalently linked to the IL-15Rα domain to form an IL-15/IL-15Rα-Fc fusion protein complex, wherein the IL-15 polypeptide is an IL-15 variant polypeptide comprising a substitution of S to D at position 58 of SEQ ID NO: 2; and wherein the fusion protein complex is selected from the group consisting of a fusion protein complex wherein the IL-15Rα domain is linked to the C-terminus of the Fc domain and a fusion protein complex wherein the IL-15Rα domain is linked to the N-terminus of the Fc domain.

6. The IL-15/IL-15Rα-Fc fusion protein complex according to claim 5 , wherein the IL-15Rα domain is an IL-15 Receptor alpha Sushi (“IL-15RαSushi”) domain and comprises an amino acid sequence that is at least 90% homologous to the sequence set forth in SEQ ID NO: 5.

7. The IL-15/IL-15Rα-Fc fusion protein complex according to claim 5 , wherein the Fc domain is an Fc domain having an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8; and wherein the IL-15 polypeptide is covalently attached to an Fc domain by a peptide linker.

8. A pharmaceutical composition comprising an IL-15/IL-15Rα-Fc fusion protein according to claim 5 in admixture with a pharmaceutically acceptable carrier.

9. An isolated IL-15 fusion protein complex comprising: (1) two IL-15 polypeptides (or variants thereof) linked to two Fc domains; and (2) two IL-15Rα domains noncovalently linked to each IL-15 polypeptide to form a dimeric IL-15/IL-15Rα-Fc fusion protein complex; wherein the IL-15 polypeptide is an IL-15 variant polypeptide comprising a substitution of S to D at position 58 of SEQ ID NO: 2; wherein the dimeric fusion protein complex is selected from the group consisting of a dimeric fusion protein complex wherein the two IL-15 polypeptides are linked to the C-terminus of the two Fc domains and a dimeric fusion protein complex wherein the two IL-15 polypeptides are linked to the N-terminus of the two Fc domains.

10. A pharmaceutical composition comprising an IL-15/IL-15Rα-Fc fusion protein according to claim 9 in admixture with a pharmaceutically acceptable carrier.

11. An isolated IL-15 fusion protein complex comprising: (1) two IL-15Rα domains linked to two Fc domains; and (2) two IL-15 polypeptides (or variants thereof) noncovalently linked to the IL-15Rα domain to form a dimeric IL-15/IL-15Rα-Fc fusion protein complex, wherein at least one of the IL-15 polypeptides is an IL-15 variant polypeptide comprising an amino acid substitution of S to D at position 58 of SEQ ID NO: 2; and wherein the dimeric fusion protein complex is selected from the group consisting of a dimeric fusion protein complex wherein the two IL-15Rα domains are linked to the C-terminus of the two Fc domains and a dimeric fusion protein complex wherein the two IL-15Rα domains are linked to the N-terminus of the two Fc domains.

12. A pharmaceutical composition comprising an IL-15/IL-15Rα-Fc fusion protein according to claim 11 in admixture with a pharmaceutically acceptable carrier.

Continuity (2)
Provisional Application 62689051 · Jun 22, 2018
Related Publication 20220106374A1 · Apr 7, 2022
References Cited (34)
US 9328159B2 · Wong et al. · 2016 [cited by applicant]
US 9428573B2 · Wong et al. · 2016 [cited by applicant]
US 9493533B2 · Bernard et al. · 2016 [cited by applicant]
US 10206980B2 · Qu et al. · 2019 [cited by applicant]
US 10265382B2 · Felber et al. · 2019 [cited by applicant]
US 10335460B2 · Felber et al. · 2019 [cited by applicant]
US 10550185B2 · Bernett et al. · 2020 [cited by applicant]
US 10611812B2 · Wang et al. · 2020 [cited by applicant]
US 20060236411A1 · Dreher et al. · 2006 [cited by applicant]
US 20060257361A1 · Watanabe et al. · 2006 [cited by applicant]
US 20090238791A1 · Jacques et al. · 2009 [cited by applicant]
US 20140120096A1 · Bakker et al. · 2014 [cited by applicant]
US 20160355567A1 · Wong et al. · 2016 [cited by applicant]
US 20190209653A1 · Felber · 2019 [cited by applicant]
US 20210106655A1 · Qu · 2021 [cited by applicant]
EP 3093295 · 2016 [cited by applicant]
WO 1998050431 · 1998 [cited by applicant]
WO 2014066527 · 2014 [cited by applicant]
WO 2017046200 · 2017 [cited by applicant]
WO 2019006472 · 2019 [cited by applicant]
Guo et al. Immunobiology of the IL-15/IL-15Ralpha complex as an antitumor and antiviral agent. Cytokine & Growth Factor Reviews, 38:10-21 (Sep. 1, 2017). [cited by applicant]
Chirifu M et al. Crystal structure of the IL-15-IL-15Ra complex, a cytokine-receptor unit presented in trans. Nature Immunol. 8(9): 1001-1007 (2007). [cited by applicant]
Hezareh M et al. Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1. J Virol 75: 12161-8 (2001). [cited by applicant]
Hu Q et al. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy. Scientific Reports 8:7675 (2018). [cited by applicant]
Mortier E et al. Soluble Interleukin-15 Receptor a (IL-15Rα)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rβ/γ. J Biol Chem 281:1612-1619 (2006). [cited by applicant]
NG SSM et al. Heterodimeric IL-15 Treatment Enhances Tumor Infiltration, Persistence and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion. Clin Cancer Res 23(11): 281… [cited by applicant]
Ring AM et al. Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15. Nat Immunol 13(12): 1187-1195 (2012). [cited by applicant]
Shields RL et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6… [cited by applicant]
Spangler JB et al. Insights into Cytokine-Receptor Interactions from Cytokine Engineering. Annu Rev Immunol 33: 139-167 (2015). [cited by applicant]
Steel JC et al. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 33(1): 35-41 (2012). [cited by applicant]
Vincent M et al. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. OncoImmunology 2:11, e26441 (2013). [cited by applicant]
Wrangle JM et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19: 694-704 (2018). [cited by applicant]
Xu W et al. Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor α/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma. Cancer Res 73(10); 3075-86 (2013). [cited by applicant]
PCT International Search Report-Written Opinion, Oct. 2, 2019. [cited by applicant]